Dr. Reddy's Laboratories Limited
RDYHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 17, 2026
Scan Results
Daily timeframeOperating under the Drug Manufacturers - Specialty & Generic umbrella, Dr. Reddy's Laboratories Limited is a healthcare company. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The $10.58B market capitalization puts RDY squarely in large-cap range for its industry. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Market Cap
$10.58B
Beta
0.26
P/E (TTM)
23.09
P/E (Fwd)
19.34
EPS (TTM)
$0.55
EPS (Fwd)
$0.66
ROE
11.8%
ROA
5.7%
Cash
$87.81B
Total Debt
$77.34B
Free CF
$1.63B
52W Change
-13.6%
Annual Financials
Cash vs Debt
Dr. Reddy's Laboratories Limited holds $87.81B in cash against $77.34B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $1.63B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $245.88B (2023) to $335.93B (2026), reflecting a 37% increase over the period.
With a beta below 0.7, Dr. Reddy's Laboratories Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RDY.